open access

Vol 51, No 1 (2017)
Original research articles
Submitted: 2016-06-20
Get Citation

Cognitive impairment and BDNF serum levels

Joanna Siuda, Maja Patalong-Ogiewa, Weronika Żmuda, Magdalena Targosz-Gajniak, Ewa Niewiadomska, Iwona Matuszek, Halina Jędrzejowska-Szypułka, Monika Rudzińska-Bar
DOI: 10.1016/j.pjnns.2016.10.001
·
Neurol Neurochir Pol 2017;51(1):24-32.

open access

Vol 51, No 1 (2017)
Original research articles
Submitted: 2016-06-20

Abstract

Background/aims

To investigate the alterations of brain-derived neurotrophic factor (BNDF) serum levels in subjects with different intensity of cognitive impairment and different neurodegenerative processes.

Material and methods

Serum BDNF levels were analyzed by ELISA kit in 378 subjects: 134 Alzheimer's disease (AD) patients, 115 amnestic mild cognitive impairment (MCI) patients, and 129 controls divided into two groups: neurodegenerative control group (ND), consisting of 49 Parkinson's disease patients without any cognitive complaints, and cognitively normal control group (CN), consisting of 80 subjects without any neurological disorders.

Results

AD patients had significantly lower (p<0.001) BDNF serum levels compared to MCI, CN and ND controls. Age and education had significant influence on BDNF serum levels regardless the diagnosis or group assignment. We have found no influence of depression on BDNF serum levels either in our group as a whole, or in each group assessed separately. We found significant correlation between BDNF serum levels and cognitive impairments. After multiple comparisons between the groups, we found that, after adjustment for confounding factors (age, gender, education, depression, cognitive impairment), BDNF serum levels were the lowest in AD group (p=0.05).

Conclusions

Advanced age and low educational level are associated with decreased BDNF serum levels. Decreased BDNF serum levels correspond to the severity of cognitive impairment. There is no correlation between BDNF serum levels and depressive symptoms.

Abstract

Background/aims

To investigate the alterations of brain-derived neurotrophic factor (BNDF) serum levels in subjects with different intensity of cognitive impairment and different neurodegenerative processes.

Material and methods

Serum BDNF levels were analyzed by ELISA kit in 378 subjects: 134 Alzheimer's disease (AD) patients, 115 amnestic mild cognitive impairment (MCI) patients, and 129 controls divided into two groups: neurodegenerative control group (ND), consisting of 49 Parkinson's disease patients without any cognitive complaints, and cognitively normal control group (CN), consisting of 80 subjects without any neurological disorders.

Results

AD patients had significantly lower (p<0.001) BDNF serum levels compared to MCI, CN and ND controls. Age and education had significant influence on BDNF serum levels regardless the diagnosis or group assignment. We have found no influence of depression on BDNF serum levels either in our group as a whole, or in each group assessed separately. We found significant correlation between BDNF serum levels and cognitive impairments. After multiple comparisons between the groups, we found that, after adjustment for confounding factors (age, gender, education, depression, cognitive impairment), BDNF serum levels were the lowest in AD group (p=0.05).

Conclusions

Advanced age and low educational level are associated with decreased BDNF serum levels. Decreased BDNF serum levels correspond to the severity of cognitive impairment. There is no correlation between BDNF serum levels and depressive symptoms.

Get Citation

Keywords

Brain-derived neurotrophic factor, Serum brain-derived neurotrophic factor level, Cognitive impairment, Dementia, Alzheimer' s disease

About this article
Title

Cognitive impairment and BDNF serum levels

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 51, No 1 (2017)

Pages

24-32

DOI

10.1016/j.pjnns.2016.10.001

Bibliographic record

Neurol Neurochir Pol 2017;51(1):24-32.

Keywords

Brain-derived neurotrophic factor
Serum brain-derived neurotrophic factor level
Cognitive impairment
Dementia
Alzheimer's disease

Authors

Joanna Siuda
Maja Patalong-Ogiewa
Weronika Żmuda
Magdalena Targosz-Gajniak
Ewa Niewiadomska
Iwona Matuszek
Halina Jędrzejowska-Szypułka
Monika Rudzińska-Bar

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl